CompletedNCT00539071
Higher-dose long-acting risperidone for schizophrenia that has not improved
About this title
High Dose Risperidone Consta for Patients With Schizophrenia With Poor Response to Risperidone
Read the official source — NCT00539071Medication studyAges 18–65United States
Understand this study
Who was this study for?
This study was for people with schizophrenia. Listed age limits: 18 years to 65 years. Other eligibility criteria applied.
- Listed locations
- NashvilleSee all locations and recruitment
- Study phase
- Phase 4Usually happens after approval, to monitor real-world use, safety, and longer-term outcomes.
Study information
Study start dateStarted: March 2008
- Recruitment status
- Completed
- Enrollment listed in the registry
- 160
- Sponsor
- Northwestern University
- Sponsor type
- University
- Study type
- Drug
- Intervention type
- Medication / drug
- Study phase
- Phase 4Usually happens after approval, to monitor real-world use, safety, and longer-term outcomes.
- Locations
- United States
- Age range
- From 18 Years to 65 Years
- Official registry ID
- NCT00539071
- Official title
Show the full official title
High Dose Risperidone Consta for Patients With Schizophrenia With Unsatisfactory Response to Standard Dose Risperidone or Long-Acting Injectable
Get this study by email
Recruitment & locations
CompletedNashville
Questions about this study
Who is behind this study?
The study sponsor is Northwestern University, a university.
Did this study involve medication?
Yes. The study involved medication, including long-acting injectable risperidone, long acting injectable risperidone, Conventional Dose Group and long acting injectable risperidone, High Dose Group.
Who was this study for?
This study was for people with schizophrenia. Listed age limits: 18 years to 65 years. Other eligibility criteria applied.
Want to explore more studies?
Explore studiesRelated studies
Paliperidone Palmitate Compared With Oral Antipsychotic Treatment for schizophrenia
18F-Dihydroxyphenylalanine (DOPA) Positron Emission Tomography (PET) Study to Explore Dopamine Synthesis Capacity in the Whole Striatum After 2 Weeks of Treatment With Ralmitaront or Placebo in Participants With Schizophrenia